Moreover, the combination of atezolizumab with bevacizumab shows longer PFS than atezolizumab alone in patients with unresectable HCC, given the co-activation of VEGF signaling pathway and tumor immune microenvironment [92,93]. Here, VEGFA is linked to neoplasm.